MedTrace Logo

A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

NCT07349329 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2026-01-16

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.

Conditions

  • Axial Spondyloarthritis, Non-Radiographic

Interventions

DRUG

608

608 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qinghong Zhou, BS · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

  • Xiaofeng Zeng, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2028-04-19
Completion
2029-02-21

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07349329 on ClinicalTrials.gov